# Noxxon Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/noxxon-pharma

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.noxxon.com
- Total disclosed funding: $93M
- Latest round: Series D (Oct 12, 2010)
- Investors on record: 11

## About

Noxxon Pharma AG is a clinical-stage biotechnology company focused on developing innovative therapies targeting aggressive cancers through modulation of the tumor microenvironment.Noxxon Pharma AG, founded in 1998, operates from Berlin, Germany, and specializes in developing therapies for aggressive cancers. The company has undergone strategic pivots to enhance its R&D focus. Led by CEO Aram Mangasarian, Noxxon Pharma has raised a total of EUR 17.000 mn, with the latest funding round being a PIPE of EUR 17.000 mn from Atlas Special Opportunities LLC on September 28, 2016.Noxxon Pharma specializes in developing innovative therapies aimed at treating aggressive cancers by focusing on the tumor microenvironment (TME). Their core product, NOX-A12, is designed to disrupt tumor protection mechanisms, enhancing the immune system's ability to combat cancer cells. This technology works synergistically with other treatments, such as anti-VEGF therapies and radiotherapy, to improve therapeutic outcomes. The company is actively pursuing clinical applications of its products in challenging malignancies, including glioblastoma and pancreatic cancer, which have demonstrated promising preliminary results. Noxxon Pharma's offerings are being developed for markets in North America and Europe, targeting healthcare providers, research institutions, and ultimately patients afflicted with hard-to-treat cancers.Noxxon Pharma operates within a clinical-stage revenue model that includes partnerships and collaborations with research institutions and pharmaceutical companies. Revenue transactions stem primarily from collaborative agreements, where Noxxon Pharma provides its proprietary technologies and therapies in exchange for funding and shared research objectives. This structure may involve milestone payments contingent on clinical trial progress, as well as royalties on future product sales. The company’s revenue for the most recent year, 2022, was EUR 0, with an EBITDA of EUR -12,579,197.4. The company’s flagship product, NOX-A12, is central to these agreements, facilitating the development of therapies that address significant unmet medical needs in oncology.Noxxon Pharma plans to expand its clinical pipeline with upcoming products designed to treat aggressive cancers, leveraging recent funding to support ongoing research. The company aims to penetrate new markets in North America and Europe by focusing on key regions by 2025. The funding raised in previous placements, including EUR 1 million in August 2019 and EUR 5.5 million from Nyenburgh Investment Partners, will be utilized to enhance R&D efforts and accelerate the clinical development of NOX-A12 and other potential therapies.

## Funding rounds

- Series D, Oct 12, 2010, $2.8M — Julip Run Capital
- Series D, May 19, 2010, $41M — Sofinnova Partners, TVM Capital Life Science, Andera Partners, Seventure Partners, NGN Capital, IBG Management, Dow Venture Capital, Hauck & Aufhauser Asset Management Services, VC Fonds Technologie Berlin, Dieckell Vermogensverwaltung
- Series C, May 3, 2007, $49M — Sofinnova Partners, TVM Capital Life Science, Andera Partners, Seventure Partners, IBG Management, Dow Venture Capital

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series C, Series D
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series C, Series D
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series C, Series D
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series C, Series D
- IBG Management (https://capitalatlas.ai/funds/ibg-management) — Series C, Series D
- Dow Venture Capital (https://capitalatlas.ai/funds/dow-venture-capital) — Series C, Series D
- NGN Capital (https://capitalatlas.ai/funds/ngn-capital) — Series D
- Hauck & Aufhauser Asset Management Services — Series D
- VC Fonds Technologie Berlin — Series D
- Dieckell Vermogensverwaltung — Series D
- Julip Run Capital (https://capitalatlas.ai/funds/julip-run-capital) — Series D